Zeping Wang1, Maura M Manion2, Elizabeth Laidlaw2, Adam Rupert3, Chuen-Yen Lau4, Bryan R Smith5, Avindra Nath5, Irini Sereti2, Dima A Hammoud1. 1. Center for Infectious Disease Imaging, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health. 2. Laboratory of Immunoregulation, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda. 3. Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick. 4. National Institute for Allergy and Infectious Diseases, National Institutes of Health. 5. Section of Infections of the Nervous System, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland, USA.
Abstract
OBJECTIVE: We evaluated brain glucose metabolism in people living with HIV (PWH) with [18F]-Fluoro-Deoxyglucose (FDG) PET/computed tomography (CT) before and after antiretroviral therapy (ART) initiation. DESIGN: We conducted a longitudinal study wherein ART-naive late-presenting untreated PWH with CD4+ cell counts less than 100 cells/μl were prospectively assessed for FDG uptake at baseline and at 4-8 weeks (n = 22) and 19-26 months (n = 11) following ART initiation. METHODS: Relative uptake in the subcortical regions (caudate, putamen and thalamus) and cortical regions (frontal, parietal, temporal and occipital cortices) were compared across time and correlated with biomarkers of disease activity and inflammation, in addition to being compared with a group of uninfected individuals (n = 10). RESULTS: Before treatment initiation, putaminal and caudate relative FDG uptake values in PWH were significantly higher than in uninfected controls. Relative putaminal and thalamic uptake significantly decreased shortly following ART initiation, while frontal cortex values significantly increased. FDG uptake changes correlated with changes in CD4+ cell counts and viral load, and, in the thalamus, with IL-6R and sCD14. Approximately 2 years following ART initiation, there was further decrease in subcortical relative uptake values, reaching levels below those of uninfected controls. CONCLUSION: Our findings support pretreatment basal ganglia and thalamic neuroinflammatory changes in PWH, which decrease after treatment with eventual unmasking of long-term irreversible neuronal damage. Meanwhile, increased frontal cortex metabolism following ART initiation suggests reversible cortical dysfunction which improves with virologic control and increased CD4+ cell counts. Early initiation of treatment after HIV diagnosis and secondary control of inflammation are thus necessary to halt neurological damage in PWH.
OBJECTIVE: We evaluated brain glucose metabolism in people living with HIV (PWH) with [18F]-Fluoro-Deoxyglucose (FDG) PET/computed tomography (CT) before and after antiretroviral therapy (ART) initiation. DESIGN: We conducted a longitudinal study wherein ART-naive late-presenting untreated PWH with CD4+ cell counts less than 100 cells/μl were prospectively assessed for FDG uptake at baseline and at 4-8 weeks (n = 22) and 19-26 months (n = 11) following ART initiation. METHODS: Relative uptake in the subcortical regions (caudate, putamen and thalamus) and cortical regions (frontal, parietal, temporal and occipital cortices) were compared across time and correlated with biomarkers of disease activity and inflammation, in addition to being compared with a group of uninfected individuals (n = 10). RESULTS: Before treatment initiation, putaminal and caudate relative FDG uptake values in PWH were significantly higher than in uninfected controls. Relative putaminal and thalamic uptake significantly decreased shortly following ART initiation, while frontal cortex values significantly increased. FDG uptake changes correlated with changes in CD4+ cell counts and viral load, and, in the thalamus, with IL-6R and sCD14. Approximately 2 years following ART initiation, there was further decrease in subcortical relative uptake values, reaching levels below those of uninfected controls. CONCLUSION: Our findings support pretreatment basal ganglia and thalamic neuroinflammatory changes in PWH, which decrease after treatment with eventual unmasking of long-term irreversible neuronal damage. Meanwhile, increased frontal cortex metabolism following ART initiation suggests reversible cortical dysfunction which improves with virologic control and increased CD4+ cell counts. Early initiation of treatment after HIV diagnosis and secondary control of inflammation are thus necessary to halt neurological damage in PWH.
Authors: Ronald J Ellis; Jayraan Badiee; Florin Vaida; Scott Letendre; Robert K Heaton; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Susan Morgello; J Allen McCutchan; Igor Grant Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant Journal: Neurology Date: 2010-12-07 Impact factor: 9.910
Authors: S Czub; M Czub; E Koutsilieri; S Sopper; F Villinger; J G Müller; C Stahl-Hennig; P Riederer; V Ter Meulen; G Gosztonyi Journal: Acta Neuropathol Date: 2004-01-08 Impact factor: 17.088
Authors: Asante R Kamkwalala; Xuzhi Wang; Pauline M Maki; Dionna W Williams; Victor G Valcour; Alexandra Damron; Phyllis C Tien; Kathleen M Weber; Mardge H Cohen; Erin E Sundermann; Vanessa J Meyer; Deborah M Little; Yanxun Xu; Leah H Rubin Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771